{
    "2018-11-14": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Migraine-Focused Biotech Has A Headache On Quarterly Losses",
                "features": {
                    "keywords": [
                        "migraine-focused",
                        "biotech",
                        "quarterly losses"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Can These 2 Battered Biotech Stocks Recover?",
                "features": {
                    "keywords": [
                        "battered",
                        "biotech stocks",
                        "recover"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Roche's Tecentriq Gets Priority Review for Breast Cancer",
                "features": {
                    "keywords": [
                        "Roche",
                        "Tecentriq",
                        "priority review",
                        "breast cancer"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Novartis AG (NVS) Not Doing Enough to Attract Smart Money",
                "features": {
                    "keywords": [
                        "Novartis AG",
                        "smart money",
                        "not doing enough"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}